Dr. Michael Klaper advocates a plant-based “whole food” diet and water fasts as the cure for what ails you, with demonstrably overblown claims for the benefits of such practices and invocation of nonsense “detoxification”? Yet Penn Jillette gave him a friendly forum on his podcast. Where did the Penn of “Penn & Teller: Bullshit!” go? Here we examine Dr. Klaper’s claims and find them weak on science.
A recent spate of articles over the last couple of days report that Elle Macpherson is dating an antivaccine “icon,” disgraced antivaccine doctor and scientific fraud Andrew Wakefield. Given her love of “alkaline diet” woo, which she sells through her very Goop-like Wellco website, the attraction shouldn’t be surprising. It is, nonetheless, troubling. It wouldn’t surprise me if Macpherson is antivaccine herself, given that in “alkaline diet” lingo, vaccines are often viewed as “toxic acid” insults that “alkalinization” can reverse.
Last week, we learned that antivaccine pediatrician Dr. Bob Sears was disciplined by the Medical Board of California. It didn’t take long for him to take to Facebook to make excuses and paint himself as a martyr to the “vaccine freedom” cause or for his antivaccine admirers to come up with ridiculous conspiracy theories.
On Wednesday, President Trump signed a federal right-to-try bill into law with great fanfare, making extravagant claims for it. It’s time to reiterate one last time that right-to-try will not help terminally ill patients but it will strip important protections from them. It’s pure snake oil.
“Right-to-try” laws are a cruel sham that purport to allow terminally ill patients access to promising experimental drugs. In reality, they strip away many protections and leave vulnerable patients on their own. After four years and a number of toothless state laws, a federal version of “right-to-try” has passed Congress and is poised to become law. Once President Trump signs the bill this week, this federal version of “right-to-try” will leave terminally ill patients on their own and will likely be the first step in returning the FDA to its pre-thalidomide state, in which it only required evidence of safety, not efficacy, to approve drugs.
